Receipt of Promotional Payments at the Individual and Physician Network Level Associated with Higher Branded Antipsychotic Prescribing Rates
- 4 Downloads
Pharmaceutical promotion can lead to market size expansion, which is beneficial if previously untreated patients access treatment but deleterious if it leads to overuse, an area of concern for second generation antipsychotics (SGA). We contribute to a growing body of work suggesting that networks of social and professional relationships shape prescribing behavior. We examined 88,439 Medicare Part D prescribing physicians, finding that promotion is associated with SGA market size expansion (elasticity: 0.062) and that network-level promotional activity is associated with network members’ branded product prescribing. Research on the effects of promotion should account for its effects in prescribers’ networks.
KeywordsMedicare Physician behavior Pharmaceutical promotion Social network analysis
I gratefully acknowledge Dr. Marcela-Horvitz-Lennon, and Dr. Sharon-Lise Normand for their support and mentorship, reviews, and methodological advice. Additionally, I would like to acknowledge Lisa Jonsson, Michele Abbot, Sara Turner, Sujeong Park, Rouslan Karimov, PhuongGiang Nguyen, and Dr. Dmitry Khodyakov for their helpful comments.
Financial support for this study was provided in part by grants from the National Institute of Mental Health (R01-MH106682), the National Institute of Minority Health and Health Disparities (R01-MDO12428), and the Anne and James Rothenberg Dissertation Award. The funding agreements ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report.
Compliance with Ethical Standards
Conflicts of interest
The author declare that he has no conflict of interest.
Research Involving Human Participants and/or Animals/Informed Consent
This study uses publicly available, secondary data and was approved by the RAND Human Subjects Protection Committee.
- American College of Neuropsychopharmacology. (2004). Executive summary: Preliminary report of the task force on SSRIs and suicidal behaviour in youth. Retrieved June, 2019 from https://acnp.org/wp-content/uploads/2017/10/Task-Force-Report-on-SSRIs-and-Suicide-in-Youth-Exec-Summary.pdf.
- Borkowski, L., Fugh‐Berman, A., Mullins, P., & Wood, S. F. (2012). Impacts of pharmaceutical marketing on healthcare services in the District of Columbia: Focus on antipsychotics in children. Retrieved June, 2019 from https://doh.dc.gov/sites/default/files/dc/sites/doh/publication/attachments/Impacts%20of%20Pharmaceutical%20Marketing%20on%20Healthcare%20Services%20in%20the%20District%20of%20Columbia%20-%20with%20logo.pdf.
- Carton, L., Cottencin, O., Lapeyre-Mestre, M., Geoffroy, P. A., Favre, J., Simon, N., et al. (2015). Off-label prescribing of antipsychotics in Adults, Children and elderly individuals: A systematic review of recent prescription trends. Current Pharmaceutical Design, 21(23), 3280–3297.CrossRefGoogle Scholar
- Centers for Medicare and Medicaid Services. (2015). Medicaid drug spending dashboard. Retrieved from https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Dashboard/2015-Medicaid-Drug-Spending/2015-Medicaid-Drug-Spending.html.
- Centers for Medicare and Medicaid Services. (2017). Open payments public use files: Methodology overview & data dictionary. Retrieved July, 2017 from https://www.cms.gov/OpenPayments/Downloads/OpenPaymentsDataDictionary.pdf.
- CMS Office of Enterprise Data and Analytics. (2019). Medicare fee-for service provider utilization & payment data part D prescriber public use file: A methodological overview. Retrieved May, 2019 from https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Downloads/Prescriber_Methods.pdf.
- Coleman, J. S., Katz, E., & Menzel, H. (1967). Medical innovation: A diffusion study. Inidianapolis: The Bobbs-Merril Company Inc.Google Scholar
- Cunningham, F. C., Ranmuthugala, G., Plumb, J., Georgiou, A., Westbrook, J. I., & Braithwaite, J. (2012). Health professional networks as a vector for improving healthcare quality and safety: A systematic review. BMJ Qual Saf, 21(3), 239–249. https://doi.org/10.1136/bmjqs-2011-000187.CrossRefGoogle Scholar
- David, G. M., & Richards-Shubik, S. S. (2010). The effects of pharmaceutical marketing and promotion on adverse drug events and regulation. American Economic Journal: Economic Policy, 2, 1–25.Google Scholar
- DeJong, C., Aguilar, T., Tseng, C. W., Lin, G. A., Boscardin, W. J., & Dudley, R. A. (2016). Pharmaceutical industry-sponsored meals and physician prescribing patterns for medicare beneficiaries. JAMA Internal Medicine, 176(8), 1110–1114. https://doi.org/10.1001/jamainternmed.2016.2765.CrossRefGoogle Scholar
- DeJong, J. D., Westert, G. P., Lagoe, R., & Groenewegen, P. P. (2006). Variation in hospital length of stay: Do physicians adapt their length of stay decisions to what is usual in the hospital where they work? Health Services Research, 41(2), 374–394. https://doi.org/10.1111/j.1475-6773.2005.00486.x.CrossRefGoogle Scholar
- Galling, B., Roldan, A., Hagi, K., Rietschel, L., Walyzada, F., Zheng, W., et al. (2017). Antipsychotic augmentation vs. monotherapy in schizophrenia: Systematic review, meta-analysis and meta-regression analysis. World Psychiatry, 16(1), 77–89. https://doi.org/10.1002/wps.20387.CrossRefGoogle Scholar
- Iles, V. S., Kim (2001). Organisational Change A Review for Health Care Managers, Professionals and Researchers National Coordinating Centre for NHS Service Delivery and Organisation, London.Google Scholar
- Kreyenbuhl, J. A., Valenstein, M., McCarthy, J. F., Ganoczy, D., & Blow, F. C. (2007). Long-term antipsychotic polypharmacy in the VA health system: Patient characteristics and treatment patterns. Psychiatric Services (Washington, D. C.), 58(4), 489–495. https://doi.org/10.1176/ps.2007.58.4.489.CrossRefGoogle Scholar
- Lo, B., & Field, M. (2009). Conflict of interest in medical research, education, and practice. Washington, DC: Institute of Medicine.Google Scholar
- Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J. H., Ewing, B., et al. (2011). Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. JAMA, 306(12), 1359–1369. https://doi.org/10.1001/jama.2011.1360.CrossRefGoogle Scholar
- Meltzer, D., Chung, J., Khalili, P., Marlow, E., Arora, V., Schumock, G., et al. (2010). Exploring the use of social network methods in designing healthcare quality improvement teams. Social Science and Medicine, 71(6), 1119–1130. https://doi.org/10.1016/j.socscimed.2010.05.012.CrossRefGoogle Scholar
- Meyer, J. M., Davis, V. G., Goff, D. C., McEvoy, J. P., Nasrallah, H. A., Davis, S. M., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1. Schizophrenia Research, 101(1–3), 273–286. https://doi.org/10.1016/j.schres.2007.12.487.CrossRefGoogle Scholar
- Mulcahy, A. W., Normand, S. L., Newcomer, J. W., Colaiaco, B., Donohue, J. M., Lave, J. R., et al. (2017). Simulated effects of policies to reduce diabetes risk among adults with schizophrenia receiving antipsychotics. Psychiatric Services (Washington, D. C.), 68(12), 1280–1287. https://doi.org/10.1176/appi.ps.201500485.CrossRefGoogle Scholar
- Office of the Inspector General. (2003). Compliance program guidance for pharmaceutical manufacturers. Retrieved August, 2018 from https://oig.hhs.gov/fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf.
- Orszag, P. R. (2008). The overuse, underuse, and misuse of health care. Retrieved August, 2018 from https://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/95xx/doc9567/07-17-healthcare_testimony.pdf.
- Pimentel, C. B., Donovan, J. L., Field, T. S., Gurwitz, J. H., Harrold, L. R., Kanaan, A. O., et al. (2015). Use of atypical antipsychotics in nursing homes and pharmaceutical marketing. Journal of the American Geriatrics Society, 63(2), 297–301. https://doi.org/10.1111/jgs.13180.CrossRefGoogle Scholar
- Senge, P. (1990). The Fifth Discipline: The art and practice of the learning organisation. London: Doubleday/Century Business.Google Scholar
- Sridhar, S. M., Murali, K., & Albers, Sönke. (2014). Pharmaceutical Detailing elasticities: A meta-analysis. In J. E. A. S. S. MinDing (Ed.), Innovation and marketing in the pharmaceutical industry, emerging pactices, research, and policies. New York: Springer.Google Scholar
- Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., et al. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). American Journal of Psychiatry, 168(9), 947–956. https://doi.org/10.1176/appi.ajp.2011.10111609.CrossRefGoogle Scholar
- Trotter, F. (2017). CareSet Labs Releases Root NPI Graph—A Greatly Improved Medicare Doctor Referral Dataset. Retrieved August, 2018 from https://careset.com/rootnpigraph/.
- United States Department of Justice. (2009). Eli Lilly and company agrees to pay $1.415 billion to resolve allegations of off-label promotion of zyprexa [Press release]. Retrieved June, 2019 from https://www.justice.gov/archive/opa/pr/2009/January/09-civ-038.html.
- U.S. Department of Health and Human Services. (2011). Medicare atypical antipsychotic drug claims for elderly nursing home residents (OIG publication No. OEI-07-08-00150). Washington, DC. Retrieved June, 2019 from http://oig.hhs.gov/oei/reports/oei-07-08-00150.pdf.
- Valuck, R. J., Morrato, E. H., Dodd, S., Oderda, G., Haxby, D. G., Allen, R., et al. (2007). How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs. Current Medical Research and Opinion, 23(10), 2567–2576. https://doi.org/10.1185/030079907x233214.CrossRefGoogle Scholar
- Vancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., et al. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: A systematic review and meta-analysis. World Psychiatry, 14(3), 339–347. https://doi.org/10.1002/wps.20252.CrossRefGoogle Scholar
- VOXX Analytics. (2017). VOXX products. Retrieved August, 2018 from http://www.voxxanalytics.com/products.
- Wilson, D. (2010). Side Effects May Include Lawsuits. New York Times Retrieved from http://www.nytimes.com/2010/10/03/business/03psych.html?pagewanted=all.